Wang Jian-Hong, Guo Lei, Wang Su, Yu Neng-Wei, Guo Fu-Qiang
Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072, China.
Department of Neurosurgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072, China.
Curr Opin Pharmacol. 2022 Feb;62:15-22. doi: 10.1016/j.coph.2021.10.005. Epub 2021 Dec 7.
β-Hydroxybutyl acid (βOHB), the most prevalent type of ketone in the human body, is involved in the pathogenesis of cognitive disorders, especially Alzheimer's dementia (AD), through a variety of mechanisms, such as enhancing mitochondrial metabolism, regulating signaling molecule, increasing histone acetylation, affecting the metabolism of Aβ and Tau proteins, inhibiting inflammation and lipid metabolism, and regulating intestinal microbes. Based on the above findings, clinical drug development in AD has begun to focus on βOHB.
β-羟基丁酸（βOHB）是人体中最常见的酮类，通过多种机制参与认知障碍的发病过程，尤其是阿尔茨海默病（AD），这些机制包括增强线粒体代谢、调节信号分子、增加组蛋白乙酰化、影响淀粉样β蛋白（Aβ）和tau蛋白的代谢、抑制炎症和脂质代谢以及调节肠道微生物。基于上述发现，AD的临床药物开发已开始聚焦于βOHB。
